Article Text

other Versions

PDF
Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer
  1. Koichi Wako (kwako{at}med.niigata-u.ac.jp)
  1. Niigata University Graduate School of Medical and Dental Sciences, Japan
    1. Takashi Kawasaki
    1. Niigata University Graduate School of Medical and Dental Sciences, Japan
      1. Kazutoshi Yamana
      1. Niigata University Graduate School of Medical and Dental Sciences, Japan
        1. Kazuya Suzuki
        1. Niigata University Graduate School of Medical and Dental Sciences, Japan
          1. Shuying Jiang
          1. Niigata University Graduate School of Medical and Dental Sciences, Japan
            1. Hajime Umezu
            1. Niigata University Graduate School of Medical and Dental Sciences, Japan
              1. Tsutomu Nishiyama
              1. Niigata University Graduate School of Medical and Dental Sciences, Japan
                1. Kota Takahashi
                1. Niigata University Graduate School of Medical and Dental Sciences, Japan
                  1. Takao Hamakubo
                  1. University of Tokyo, Japan
                    1. Tatsuhiko Kodama
                    1. University of Tokyo, Japan
                      1. Makoto Naito
                      1. Niigata University Graduate School of Medical and Dental Sciences, Japan

                        Abstract

                        Aims: The association between the expression of androgen receptor (AR) or androgen-converting enzymes and malignant potential in prostate cancer (PCa) was examined.

                        Methods: PCa specimens from 44 cases of stage II, 10 cases of stage III, 4 cases of stage IV, and 2 recurrent cases were semi-quantitatively studied with immunohistochemistry for AR and androgen-converting enzymes.

                        Results: The expression score of AR, 5α-reductase type 1 (SRD5A1), 5α-reductase type 2 (SRD5A2), and aldo-keto reductase family 1 member C3 (AKR1C3) in the metastatic lesion of stage IV or recurrent cancer (n = 6) was significantly higher than stage II and III cancer (n = 54) (p<0.001, p<0.001, p = 0.002, and p = 0.018, respectively). The expression score of AR and SRD5A1 in stage II and III cancer with Gleason score 7 (n = 19) was significantly higher than that with ≤6 (n = 20) (p = 0.032 and p = 0.002, respectively), and the expression score of AR, SRD5A1, and AKR1C3 in stage II and III cancer with primary Gleason pattern ≥4 (n = 21) was significantly higher than that with ≤3 (n = 33) (p = 0.011, p = 0.026, and p = 0.034, respectively). Within Gleason score 9 cancer, the expression score of AR and SRD5A1 in the primary lesion of stage IV (n = 3) was significantly higher than stage II and III (n = 7) (p = 0.027 and p = 0.001, respectively).

                        Conclusions: Both AR and androgen-converting enzymes were upregulated in the high-grade or advanced PCa.

                        • Gleason score
                        • androgen receptor
                        • androgen-converting enzymes
                        • biological aggressiveness
                        • prostate cancer

                        Statistics from Altmetric.com

                        Request permissions

                        If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.